Dianthus Therapeutics, Inc. /DE/ (NASDAQ:DNTH)
| Market Cap | $4.76B+104.0% |
| Revenue (ttm) | $2.72M-11.7% |
| Net Income | -$39.79M+68.5% |
| EPS | -$0.71+100.9% |
| Shares Out | 56.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 784,842 |
| Open | $83.62 |
| Previous Close | $84.83 |
| Day's Range | $82.51 - $85.67 |
| 52-Week Range | $35.84 - $117.88 |
| Beta | 0.08 |
| Analysts | Buy |
| Price Target | $136.50(+61.44%) |
| Earnings Date | Mar 8, 2027 |
About DNTH
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating DNTH in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 8, 2027Earnings report
$DNTH stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in DNTH holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by DNTH's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
DNTH Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New DNTH patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to DNTH from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in DNTH
| XBIState Street SPDR S&P Biotech ETF | $120.03M |
| VTIVanguard Morningstar Total Stock Market ETF | $109.72M |
| IWMiShares Russell 2000 ETF | $105.28M |
| VXFVanguard Extended Market ETF | $52.31M |
| VBVanguard Morningstar Small-Cap ETF | $49.02M |
| IWOiShares Russell 2000 Growth ETF | $37.91M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from DNTH’s recent data — informational, not investment advice
What’s Behind the Score
News check: Analyst upside call and Q3 revenue beat offset insider selling and valuation concerns; mixed but slightly positive tone.
Recent Insider Activity
Insider Score Trend Over Time
-34.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| IBRN | iShares Neuroscience and Healthcare ETF | 3.98% |
| SBIO | ALPS Medical Breakthroughs ETF | 3.38% |
| TDNA | T. Rowe Price Biotech ETF | 1.95% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 1.91% |
| LFSC | F/M Emerald Life Sciences Innovation ETF | 1.57% |
| XBI | State Street SPDR S&P Biotech ETF | 1.29% |
| TSEE | T. Rowe Price Small Cap ETF | 0.95% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.80% |
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 0.65% |
| GDOC | Goldman Sachs Future Health Care Equity ETF | 0.62% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 0.58% |
| BMED | iShares Health Innovation Active ETF | 0.57% |
Weight is the stock’s share of each fund’s holdings.
